AL Hilal Pharmacy

AL Hilal Pharmacy is a pharmaceutical importer and distributor based in Aden, Yemen. Established in 2007, the company has been instrumental in supplying a diverse range of pharmaceutical products to the Yemeni market. Operating as a key player in Yemen's pharmaceutical distribution network, AL Hilal Pharmacy imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. The company's mission is to provide high-quality medicines at accessible prices, ensuring availability across the country.

Over the years, AL Hilal Pharmacy has developed a robust portfolio, importing a total of 109 unique formulations across five product categories. The company's strategic focus on sourcing from India has enabled it to offer a wide array of pharmaceutical products, catering to various therapeutic needs within Yemen. This approach underscores AL Hilal Pharmacy's commitment to meeting the healthcare demands of the Yemeni population through reliable and diverse pharmaceutical imports.

While specific details about AL Hilal Pharmacy's warehouse locations and logistics capabilities are not publicly disclosed, the company is known to operate from Aden, Yemen. Given Aden's strategic position as a major port city, it is likely that AL Hilal Pharmacy utilizes this advantage to facilitate the importation and distribution of pharmaceutical products. The company's distribution network is presumed to cover major cities and regions within Yemen, ensuring that imported medicines reach a broad customer base. However, without explicit information on their logistics infrastructure, a comprehensive assessment of their geographic coverage and logistics capabilities remains speculative.

AL Hilal Pharmacy plays a pivotal role in Yemen's pharmaceutical supply chain as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a steady supply of essential medicines to the Yemeni market. This role is crucial in a country where access to a diverse range of pharmaceutical products is vital for public health. Through its import and distribution activities, AL Hilal Pharmacy contributes significantly to the healthcare infrastructure of Yemen, facilitating the availability of necessary medications across the nation.

AL Hilal Pharmacy's sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from a single supplier, INNOVA CAPTAB LIMITED. This supplier accounts for approximately 97.7% of the total import value, indicating a strong reliance on this partnership. Such a concentrated sourcing approach can offer benefits like streamlined procurement processes and potentially favorable pricing. However, it also introduces risks associated with supplier dependency, including potential disruptions in supply due to issues like production delays, quality concerns, or geopolitical factors affecting trade relations.

The stability of AL Hilal Pharmacy's relationship with INNOVA CAPTAB LIMITED is suggested by the consistent volume of imports over the years. Nonetheless, the lack of diversification in sourcing could pose challenges in maintaining a continuous and reliable supply chain. To mitigate these risks, it would be prudent for AL Hilal Pharmacy to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing potential vulnerabilities associated with over-reliance on a single supplier.

The resilience of AL Hilal Pharmacy's supply chain is closely tied to its sourcing strategy, which is predominantly concentrated on a single supplier, INNOVA CAPTAB LIMITED. This concentration can lead to vulnerabilities, as any disruptions affecting this supplier—such as production issues, quality control problems, or geopolitical tensions—could significantly impact AL Hilal Pharmacy's ability to meet market demand. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies further underscores the potential risks associated with this dependency.

To bolster supply chain resilience, AL Hilal Pharmacy might consider establishing relationships with additional suppliers, both within India and internationally. Diversifying the supplier base would provide alternative sources for pharmaceutical products, thereby mitigating the impact of potential disruptions from a single supplier. Additionally, expanding the range of imported formulations could reduce the risk associated with over-reliance on specific products or therapeutic categories. Implementing these strategies would enhance the company's ability to maintain a consistent and reliable supply of medicines to the Yemeni market.

AL Hilal Pharmacy's concentrated sourcing pattern, primarily from INNOVA CAPTAB LIMITED, positions the company to benefit from streamlined procurement processes and potentially favorable pricing structures. This strategic choice may also foster strong supplier relationships, leading to better terms and priority access to products. However, the lack of supplier diversification introduces risks related to supply chain disruptions, which could affect the company's ability to meet market demand consistently.

For Indian exporters seeking to become alternative suppliers to AL Hilal Pharmacy, understanding the company's current sourcing dynamics is crucial. Offering a diverse range of high-quality pharmaceutical products and demonstrating reliability in supply can position new suppliers as attractive partners. Additionally, highlighting the ability to provide competitive pricing and flexible terms may appeal to AL Hilal Pharmacy's strategic objectives. By addressing these factors, Indian exporters can effectively position themselves as viable alternatives, potentially expanding their market presence in Yemen.

In Yemen, the primary regulatory authority overseeing pharmaceutical imports is the Ministry of Public Health and Population. This ministry is responsible for establishing and enforcing regulations related to the importation, registration, and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Customs Law No. 14 of 1990 and its subsequent amendments, which outline the procedures and requirements for importing goods into Yemen. Notably, Law No. 5 of 2020 amended the Customs Law to exempt certain pharmaceutical production inputs from customs duties, aiming to facilitate the availability of essential medicines in the country.

The marketing authorization pathway for Indian generics involves several steps. Initially, the pharmaceutical product must be registered with the Ministry of Public Health and Population, which includes submitting a Certificate of Pharmaceutical Products (COPP) issued by the competent authority in the country of origin, such as the U.S. FDA. This certificate verifies the authenticity and regulatory compliance of the product. The COPP must undergo legalization to be recognized by Yemeni authorities, a process that involves certification and embassy verification to confirm the document's authenticity.

To import pharmaceutical products into Yemen, companies must obtain an import license from the Ministry of Public Health and Population. This process requires registration as an importer with the Ministry of Industry and Trade and may involve additional licenses depending on the product category. Compliance with Good Manufacturing Practice (GMP) standards is mandatory, and imported products must be accompanied by certificates confirming adherence to recognized GMP standards, such as EU GMP, WHO GMP, or PIC/S. Additionally, wholesale distribution authorization is required to operate as a distributor within Yemen, ensuring that all imported pharmaceutical products are handled and distributed in accordance with national regulations.

Imported pharmaceutical products must undergo batch testing to ensure they meet Yemeni quality standards. Stability requirements are enforced to guarantee the efficacy and safety of medicines throughout their shelf life. Labeling must be in Arabic, providing essential information such as dosage instructions, storage conditions, and expiration dates. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the market, ensuring the integrity of the pharmaceutical supply chain.

Between 2024 and 2026, Yemen has implemented several policy changes affecting pharmaceutical imports. Notably, the amendment of the Customs Law in May 2020, which exempted certain pharmaceutical production inputs from customs duties, continues to influence the import landscape. This exemption aims to reduce costs for pharmaceutical manufacturers and improve the availability of essential medicines. While specific regulatory changes between 2024 and 2026 are not detailed in the available sources, it is advisable for stakeholders to consult the Ministry of Public Health and Population for the most current information on import regulations and policies.

AL Hilal Pharmacy's product strategy focuses on importing pharmaceutical formulations across five categories, with a significant emphasis on gastrointestinal medications (62.1%), advanced diabetes medications (27.6%), and respiratory treatments (10.3%). This strategic focus aligns with the prevalent health concerns in Yemen, where gastrointestinal disorders, diabetes, and respiratory diseases are common. By concentrating on these therapeutic areas, AL Hilal Pharmacy addresses critical healthcare needs, ensuring that essential medications are accessible to the Yemeni population.

The market demand driving these imports is influenced by factors such as the prevalence of specific diseases, demographic trends, and the availability of healthcare services. For instance, the high incidence of diabetes in Yemen necessitates a steady supply of advanced diabetes medications. Similarly, the prevalence of gastrointestinal and respiratory conditions underscores the need for effective treatments in these categories. AL Hilal Pharmacy's product strategy is thus a direct response to these market demands, aiming to improve health outcomes by providing targeted pharmaceutical solutions.

AL Hilal Pharmacy's sourcing strategy is predominantly focused on importing generic drugs, primarily from India.